[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368561-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368561-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","proposal-for-a-new-classification-of-rare-cancers-an-approach-adopting-updated-histological-tumor-types","Proposal for a New Classification of Rare Cancers - An Approach Adopting Updated Histological Tumor Types","","Several classifications have been proposed to define rare cancers, yet tumor pathophysiology changes rapidly. A New Classification of Rare Cancer (NCRC) system is proposed using the updated International Classification of Diseases for Oncology 3.2 coding and the World Health Organization Classification of Tumors (5th edition). Patient data from Japan’s National Cancer Registry (2016–2019) are re-coded with a rare-cancer cutoff of a crude incidence rate of 6 cases/100,000/year, producing a Japan-specific rare-cancer list. The system’s performance is evaluated by comparing rare/non-rare labeling versus RARECARENet, showing 6.8% switching in Europe-based labeling and highlighting major category shifts requiring validation in broader cohorts.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/proposal-for-a-new-classification-of-rare-cancers-an-approach-adopting-updated-histological-tumor-types/368561/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/proposal-for-a-new-classification-of-rare-cancers-an-approach-adopting-updated-histological-tumor-types/368561.png","ImageObject",300,407,{"name":42,"@type":43},"Fahsai","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the proposed New Classification of Rare Cancers (NCRC)?","Question",{"text":63,"@type":64},"To define rare cancers using the updated ICD for Oncology 3.2 coding system and the WHO Classification of Tumors (5th edition), reflecting rapidly evolving tumor concepts.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the study define “rare cancers” in the NCRC framework?",{"text":68,"@type":64},"It uses a crude incidence rate cutoff of 6 cases per 100,000 per year to determine which cancers qualify as rare.",{"name":70,"@type":61,"acceptedAnswer":71},"How is the NCRC performance assessed against European labeling?",{"text":72,"@type":64},"The study compares rare/non-rare status assignments against RARECARENet, finding 69,351 cases/year (6.8%) that switch status under the NCRC approach.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368561,1791444419,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Pathology International  \nORIGINAL ARTICLE   \nProposal for a New Classification of Rare Cancers Adopting Updated Histological Tumor Types  \nRyoko Rikitake1,2,3  | Yasushi Yatabe4  | Yoko Yamamoto1 | Tatsunori Shimoi2,5 | Shintaro Iwata2,6 | Yasushi Goto7 | Yu Mizushima1,3 | Akira Kawai2,6 | Takahiro Higashi1,3   \n1Division of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan | 2Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan | 3Department of Public Health and Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo,  \nJapan | 4Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan | 5Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan | 6Department of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, Tokyo,  \nJapan | 7Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan  \nCorrespondence: Yasushi Yatabe ([yyatabe@ncc.go.jp](yyatabe@ncc.go.jp)) | Takahiro Higashi ([higashi@m.u-tokyo.ac.jp](higashi@m.u-tokyo.ac.jp))  \nReceived: 6 March 2025 | Revised: 11 April 2025 | Accepted: 21 April 2025  \nFunding: This project was funded by the Ministry of Health, Labour, and Welfare Grants‐in‐Aid for Scientific Research (project name: “Research on developing a network providing cancer information and consultation support for rare cancers.” Grant number: 23EA1013) .  \nKeywords: cancer classification | International Classification of Diseases | National Cancer Registry | rare cancer | Surveillance of Rare Cancers in Europe (RARECARE)  \nABSTRACT  \nSeveral classifications have been proposed to define rare cancers; however, the pathophysiological understanding of tumors evolves rapidly. We propose a New Classification of Rare Cancer (NCRC) using the updated International Classification of Diseases for Oncology 3.2 coding system and World Health Organization Classification of Tumors 5th edition. We applied patient data recorded in the National Cancer Registry of Japan to the new classification, setting a cut‐off of a crude incidence rate of 6 cases/100 000/year to define rare cancers, and developed a list of rare cancers in Japan from 2016 to 2019 . The NCRC system identified various rare cancers, comprising 20.0% of all cancer diagnoses in this period. To examine this classification system's performance, we compared rare/non‐rare labeling of cancers by the Surveillance of Rare Cancers in Europe (RARECARENet) project and NCRC system. Compared with cases using the RARECARENet classification in Europe, 69 351 cases/year (6.8%) switched status with our classification, with 45 293 and 232 109 cases (4 years) switching from rare and non‐ rare, respectively. Major differences included diffuse large B‐cell lymphomas, some thyroid cancers, oral cavity and lip cancers, and squamous cell carcinoma of the uterine cervix. As the NCRC includes newly classified tumor entities, it warrants validation using other diverse cohorts.  \n1 | Introduction  \nCancer comprises a heterogeneous array of diseases with varying manifestations depending on site and histology [1] . Despite advances in our understanding of cancer, rare cancers remain a challenge. Their rarity impedes research efforts and limits the development of diagnostic and treatment strategies.  \nTherefore, systematic policy support is essential to address the disadvantages faced by patients with rare cancers.  \nA crucial first step in policy support is to clearly define what constitutes rare cancers. Several studies have attempted to define the corresponding frequency criteria. In the United States (US), rare cancers are defined as those with an annual incidence of  \n\n| Abbreviations: ICD‐O3.2, International Classification of Diseases for Oncology 3.2; NCRC, new classification of rare cancers; RARECARENet, Surveillance of Rare Cancers in Europe. |\n| --- |\n| This is an open access article under the terms of the Creati","cbCaitWJGAMC0xhq","https://ap.wps.com/l/cbCaitWJGAMC0xhq","pdf",394059,"English","# Introduction\n## Background: definitions and challenges of rare cancers\n## Existing criteria in the US and Europe\n## RARECARENet structure and limitations","[{\"question\":\"What is the main goal of the proposed New Classification of Rare Cancers (NCRC)?\",\"answer\":\"To define rare cancers using the updated ICD for Oncology 3.2 coding system and the WHO Classification of Tumors (5th edition), reflecting rapidly evolving tumor concepts.\"},{\"question\":\"How does the study define “rare cancers” in the NCRC framework?\",\"answer\":\"It uses a crude incidence rate cutoff of 6 cases per 100,000 per year to determine which cancers qualify as rare.\"},{\"question\":\"How is the NCRC performance assessed against European labeling?\",\"answer\":\"The study compares rare/non-rare status assignments against RARECARENet, finding 69,351 cases/year (6.8%) that switch status under the NCRC approach.\"}]","Proposal for a New Classification of Rare Cancers - An Approach Adopting Updated Histological Tumor Types | PDF",1790177501,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bc82ff9e65a8c0aae276591ff488179.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11acd79892e630bf37b0acd6c8d97f5d.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5c5f513401e5153a9aec92ac07cb242.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35dffe597dff2d1aec9ac16e9915b79b.webp",980,1287]